BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15780422)

  • 1. Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin.
    Amod F; Moodley I; Peer AK; Sunderland J; Lovering A; Wootton M; Nadvi S; Vawda F
    J Infect; 2005 Apr; 50(3):252-7. PubMed ID: 15780422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis.
    Boak LM; Li J; Spelman D; du Cros P; Nation RL; Rayner CR
    Ann Pharmacother; 2006; 40(7-8):1451-5. PubMed ID: 16772405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
    Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
    J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
    Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
    Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid.
    Corne P; Marchandin H; Macia JC; Jonquet O
    Scand J Infect Dis; 2005; 37(11-12):946-9. PubMed ID: 16308242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
    Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
    J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of linezolid versus vancomycin in the treatment of methicillin-resistant Staphylococcus aureus discitis: a controlled animal model.
    Conaughty JM; Chen J; Martinez OV; Chiappetta G; Brookfield KF; Eismont FJ
    Spine (Phila Pa 1976); 2006 Oct; 31(22):E830-2. PubMed ID: 17047530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid eradicates MRSA better than vancomycin from surgical-site infections.
    Weigelt J; Kaafarani HM; Itani KM; Swanson RN
    Am J Surg; 2004 Dec; 188(6):760-6. PubMed ID: 15619496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
    Shorr AF; Kunkel MJ; Kollef M
    J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
    Maclayton DO; Hall RG
    Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No mercy for MRSA: treatment alternatives to vancomycin and linezolid.
    Wegner DL
    MLO Med Lab Obs; 2005 Jan; 37(1):26-9. PubMed ID: 15743145
    [No Abstract]   [Full Text] [Related]  

  • 17. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.
    Jang HC; Kim SH; Kim KH; Kim CJ; Lee S; Song KH; Jeon JH; Park WB; Kim HB; Park SW; Kim NJ; Kim EC; Oh MD; Choe KW
    Clin Infect Dis; 2009 Aug; 49(3):395-401. PubMed ID: 19569970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
    Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
    J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.